FDA Grants CPI-613 Orphan Drug Status For Peripheral T-Cell Lymphoma Treatment
News
Therapeutic candidate CPI-613, developed by Rafael Pharmaceuticals, received orphan drug designation by the U.S. Food and Drug Administration for the treatment of peripheral T-cell lymphoma (PTCL). This is the fifth ... Read more